development aspects

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

6 days ago talkbio0Tagged Antibodies, Bispecific, Autoimmune, Collaboration, development aspects, Earendil Labs, Immunology, Inflammatory Bowel Diseases, sanofi

Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

7 days ago talkbio0Tagged BARDA, CHARGE Syndrome, Clinical Trials, COVID19 (disease), development aspects, GeoVax, Immunocompromised Host, pandemic preparedness, Project NextGen, Termination - Inactive Reason Code, Vaccines

GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness

Isomorphic Labs raises $600M to push AI-designed drugs into clinic

3 weeks ago talkbio0Tagged AI-designed, development aspects, Isomorphous, Laboratory test finding

Isomorphous, Laboratory test finding, development aspects, AI-designed

Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development

3 weeks ago talkbio0Tagged Aortic Valve Insufficiency, black box, Clinical Trials, Data-Driven AI, datasets, development aspects, Drug Design, RNA medicine, Transforming RNA Medicine Development

Aortic Valve Insufficiency, development aspects, RNA medicine, black box, Data-Driven AI, Transforming RNA Medicine Development, datasets, Drug Design, Clinical Trials

MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results

1 month ago talkbio0Tagged Antibody-Drug Conjugates, CD276 gene, concerns, development aspects, discontinued, Larix, MacroGenics, Malignant neoplasm of prostate, Safety, vobra

MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

3 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)